India’s drug price regulator NPPA revises maximum retail prices (MRPs) for 543 brands of anti-cancer medicines, effective November 9, in a move health experts say highlights how prior pricing may have been excessive. The revisions also involve caps on trade margins, aimed at reducing the final cost paid by patients.
Across outlets, the main focus is on how the government sets and updates pricing and what that means for affordability. NDTV emphasizes the policy mechanism—capping trade margins at 30% and revising the prices for hundreds of drug brands—framing the change as potentially lowering patients’ medicine bills. The Hindu, while also reporting the revised MRPs and the effective date, highlights criticism from health advocates that limiting trade margins alone may not be enough, and that prices should align with medical need rather than a patient’s ability to pay.
